帕金森病与动脉粥样硬化的相关性研究
|
摘要
帕金森病是一种常见的中老年人神经退行性疾病,而动脉粥样硬化亦是多发于中老年的一种复杂的血管炎症性疾病。部分帕金森病患者同时患有动脉粥样硬化,近年一些研究发现帕金森病与动脉粥样硬化在发病机制上有许多相同或相似之处。本文通过综述帕金森病与动脉粥样硬化的发病机制从而探讨两者的相关性,并探讨两者在药物治疗上的相似性,为治疗同时患有两病者提供新的治疗方向。
Parkinson's disease is a commom neurodegenerative disease in the elderly,in addition, atherosclerosis is also a complex vascular inflammatory disease occurring in middle and old age.Some patients with Parkinson's disease also have atherosclerosis,and some researches in recent years suggest that there are many same and similar points in the pathogenesis of Parkinson's Disease and atherosclerosis.This paper summarizes the pathogenesis of Parkinson's Disease and atherosclerosis to explore their correlations and the relevance of drug therapy,which can provide new treatment directions for patients with both diseases.
Parkinson's disease is a commom neurodegenerative disease in the elderly,in addition, atherosclerosis is also a complex vascular inflammatory disease occurring in middle and old age.Some patients with Parkinson's disease also have atherosclerosis,and some researches in recent years suggest that there are many same and similar points in the pathogenesis of Parkinson's Disease and atherosclerosis.This paper summarizes the pathogenesis of Parkinson's Disease and atherosclerosis to explore their correlations and the relevance of drug therapy,which can provide new treatment directions for patients with both diseases.
引文
[1]邱雅慧.血管内皮细胞的功能以及损伤修复与动脉粥样硬化[J].中国组织工程研究与临床康复,2007,11(10):1927.
[2]吕炳强,范英昌,孙连胜.丹酚B、丹参酮IIA对动脉粥样硬化家兔血清一氧氮及甘油三酯的影响[J].天津中医学院学报,2006,25(1):32.
[3]Calabrese V,Mancuso C,Calvani M,et al.Nitricoxide in the central nervous system:neuroprotection versus neurotoxicity[J].NatRev Neurosci,2007,8(10):766-775.
[4]Furchgott RF,Zaw adzki JV.The obligat ory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine[J].Nature,1980(89):288,373-376.
[5]杨永宗,阮长耿,唐朝枢,等.动脉粥样硬化性心血管病基础与临床[M].北京:科学出版社,2004:50-51.
[6]HanssonGK.Inflammation,atherosclerosis,and coronaryartery disease[J].NEnglJMed,2005,352:1685-1695.
[7]Litteljohn D,Mangano E,Clarke M,et al.Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson’s disease[J].Parkinson’s Dis,2011:713517.
[8]Hirsch EC,Hunot S.Neuroinflammation in Pakinson’s disease:a target for neuroprotection?[J].Lancet Neurol,2009,8(4):382-397.
[9]Yoneyama M,Shiba T,Hasebe S,et al.Adult neurogenesis is regulated by endogenous factos produced during neurodegeneration[J].J Pharmacol Sci,2011,115(4):425-432.
[10]Bartels AL,Leenders KL.Neuroinflammation in the pathophysiology of Pakinson’s disease:evidence from animal models to human in vivo studies with[11C]-PK11195 PET[J].Mov Disord,2007,22(13):1852-1856.
[11]Anderson G,Maes M.TRYCAT pathways Link peripheral inflammation,nic otine,somatization and depression in the etiology and course of Parkinson’s disease[J].CNS NeurolDisord Drug Targets,2014,13(1):137-149.
[12]Murphy E.Estrogen signaling and cardiovascular disease.Circ Res,2011,109:687-696.
[13]李建军.血管内皮功能障碍及其检测与防治[J].中国动脉硬化杂志,2001,9(2):175.
[14]Dluzen DE.Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system[J].Neurocytol,2000,29(5-6):387
[15]Li X,Du J R,Yu Y,et al.TanshinoneⅡA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid ballooninjured model through inhibition of MAPK signaling pathway[J].JEthnopharmacol,2010,129(2):273.
[16]李朝梁,石秋玲,朱平先.丹参酮ⅡA对动脉粥样硬化症患者血管内皮细胞功能的干预作用[J].南昌大学学报:医学版,2012,52(7):44.
[17]刘红.丹参对动脉粥样硬化家兔血清一氧化氮、血浆内皮素和脂质过氧化物的影响[J].湖北中医杂志,2001,23(8):11.
[18]徐玉英,彭普基,游言文,等.丹参酮ⅡA对帕金森大鼠黑质内磷酸化c-Jun氨基末端激酶表达的影响[J].解剖学杂志,2016,39,(4):448-451.
[19]徐玉英,彭普基,游言文,等.丹参酮ⅡA对帕金森大鼠中脑黑质内磷酸化p38MAPK的影响[J].解剖学研究,2016,38(5):355-357.
[20]潘丽婷,陈桢玥,陆国平.阿司匹林在动脉粥样硬化中的抗炎作用[J].上海交通大学学报(医学版),2012,32(04):519-523.
[21]Asanuma M,Miyazaki I,Ogawa N.Neuroprotective effects of nonsteroidal antiinflammatory on neurodegenerative disease[J].Current Pharmaceutical Design,2004,10(6):695-700.
[22]Teismann P,Ferger B.Inhibition of the cyclooxygenas isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease[J].Syn-apse,2002,39(2):167-174.
[23]C h e n H,O’R e i l l y E J,S c h w a r z c h i l d M A,e t a l.P e r i p h e r a l inflammatory biomarkers and risk of Pakinson’s disease[J].Am JEpidemiol,2008,167(1):90-95.
[24]Chen H,Zhang SM,Hernan MA,et al.Nonsteroidal anti-inflammatory drugs and the risk for Pakinson’s disease[J].Arch Neurol,2003,60(8):1059-1064.
[25]Gonzales AM,Orlando RA.Curcumin and resveratrol inhibit nuclear factorkappa B-mediated cytokine expression in adipocytes[J].Nutr Metab,2008,5:17.
[26]Shishodia S,Singh T,Chaturvedi MM.Modulation of transcription factors by curcumin[J].Adv Exp Med Biol,2007,595:127-148.
[27]Rungseesantivanon S,Thenchaisri N,Ruangvejvorachai P,et al.Curcumin supplementation could improve diabe-tes-induced endothelial dysfunction associate d with de-creased vascular superoxide production and PKC inhibition[J].BMC Complementary Altern Med,2010,10:57.
[28]Brodacki B,Staszewski J,Toczy?owska B,et al.Serum inter-leukin(IL-2,IL-10,IL-6,IL-4),TNF alpha,and INF gamma concentrations are elevated in patients with atypical and idio-pathic parkinsonism[J].Neurosci Lett,2008,441(2):158-162.
[29]Horne BD,Muhlestein JB,Carlquist JF,et al.Statin therapy interacts with cytomegalovirus seropositivity and high Creactive protein in reducing mortality among patients with angiographically significant coronary disease[J].Circulation,2003,107(2):258-263.
[30]Ulrich L,Fata VL,Plutzky J,et al.Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors[J].Circulati on,1998,97(12):1129-1135.
[31]Wolozin B,Wang SW,Li NC,et al.Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease[J].BMC Med,2007,5:20.
[32]Wahner AD,Bronstein JM,Bordelon YM,et al.Statin use and the risk of Parkinson disease[J].Neurology,2008,70:1418-1422.
[33]Kumar A,Sharma N,Gupta A,et al.Neuroprotective potential of atorvastatin and simvastatin(HMG-CoA reductase inhibitors)against6-hydroxydopamine(6-OHDA)induced Parkinson-like symptoms[J].Brain Res,2012,1471:13-22.
[34]Bosco DA,Fowler DM,Zhang Q,et al.Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerateal pha-synuclein fibrilization[J].Nat Chem Biol,2006,2:249-253.
[2]吕炳强,范英昌,孙连胜.丹酚B、丹参酮IIA对动脉粥样硬化家兔血清一氧氮及甘油三酯的影响[J].天津中医学院学报,2006,25(1):32.
[3]Calabrese V,Mancuso C,Calvani M,et al.Nitricoxide in the central nervous system:neuroprotection versus neurotoxicity[J].NatRev Neurosci,2007,8(10):766-775.
[4]Furchgott RF,Zaw adzki JV.The obligat ory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine[J].Nature,1980(89):288,373-376.
[5]杨永宗,阮长耿,唐朝枢,等.动脉粥样硬化性心血管病基础与临床[M].北京:科学出版社,2004:50-51.
[6]HanssonGK.Inflammation,atherosclerosis,and coronaryartery disease[J].NEnglJMed,2005,352:1685-1695.
[7]Litteljohn D,Mangano E,Clarke M,et al.Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson’s disease[J].Parkinson’s Dis,2011:713517.
[8]Hirsch EC,Hunot S.Neuroinflammation in Pakinson’s disease:a target for neuroprotection?[J].Lancet Neurol,2009,8(4):382-397.
[9]Yoneyama M,Shiba T,Hasebe S,et al.Adult neurogenesis is regulated by endogenous factos produced during neurodegeneration[J].J Pharmacol Sci,2011,115(4):425-432.
[10]Bartels AL,Leenders KL.Neuroinflammation in the pathophysiology of Pakinson’s disease:evidence from animal models to human in vivo studies with[11C]-PK11195 PET[J].Mov Disord,2007,22(13):1852-1856.
[11]Anderson G,Maes M.TRYCAT pathways Link peripheral inflammation,nic otine,somatization and depression in the etiology and course of Parkinson’s disease[J].CNS NeurolDisord Drug Targets,2014,13(1):137-149.
[12]Murphy E.Estrogen signaling and cardiovascular disease.Circ Res,2011,109:687-696.
[13]李建军.血管内皮功能障碍及其检测与防治[J].中国动脉硬化杂志,2001,9(2):175.
[14]Dluzen DE.Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system[J].Neurocytol,2000,29(5-6):387
[15]Li X,Du J R,Yu Y,et al.TanshinoneⅡA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid ballooninjured model through inhibition of MAPK signaling pathway[J].JEthnopharmacol,2010,129(2):273.
[16]李朝梁,石秋玲,朱平先.丹参酮ⅡA对动脉粥样硬化症患者血管内皮细胞功能的干预作用[J].南昌大学学报:医学版,2012,52(7):44.
[17]刘红.丹参对动脉粥样硬化家兔血清一氧化氮、血浆内皮素和脂质过氧化物的影响[J].湖北中医杂志,2001,23(8):11.
[18]徐玉英,彭普基,游言文,等.丹参酮ⅡA对帕金森大鼠黑质内磷酸化c-Jun氨基末端激酶表达的影响[J].解剖学杂志,2016,39,(4):448-451.
[19]徐玉英,彭普基,游言文,等.丹参酮ⅡA对帕金森大鼠中脑黑质内磷酸化p38MAPK的影响[J].解剖学研究,2016,38(5):355-357.
[20]潘丽婷,陈桢玥,陆国平.阿司匹林在动脉粥样硬化中的抗炎作用[J].上海交通大学学报(医学版),2012,32(04):519-523.
[21]Asanuma M,Miyazaki I,Ogawa N.Neuroprotective effects of nonsteroidal antiinflammatory on neurodegenerative disease[J].Current Pharmaceutical Design,2004,10(6):695-700.
[22]Teismann P,Ferger B.Inhibition of the cyclooxygenas isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease[J].Syn-apse,2002,39(2):167-174.
[23]C h e n H,O’R e i l l y E J,S c h w a r z c h i l d M A,e t a l.P e r i p h e r a l inflammatory biomarkers and risk of Pakinson’s disease[J].Am JEpidemiol,2008,167(1):90-95.
[24]Chen H,Zhang SM,Hernan MA,et al.Nonsteroidal anti-inflammatory drugs and the risk for Pakinson’s disease[J].Arch Neurol,2003,60(8):1059-1064.
[25]Gonzales AM,Orlando RA.Curcumin and resveratrol inhibit nuclear factorkappa B-mediated cytokine expression in adipocytes[J].Nutr Metab,2008,5:17.
[26]Shishodia S,Singh T,Chaturvedi MM.Modulation of transcription factors by curcumin[J].Adv Exp Med Biol,2007,595:127-148.
[27]Rungseesantivanon S,Thenchaisri N,Ruangvejvorachai P,et al.Curcumin supplementation could improve diabe-tes-induced endothelial dysfunction associate d with de-creased vascular superoxide production and PKC inhibition[J].BMC Complementary Altern Med,2010,10:57.
[28]Brodacki B,Staszewski J,Toczy?owska B,et al.Serum inter-leukin(IL-2,IL-10,IL-6,IL-4),TNF alpha,and INF gamma concentrations are elevated in patients with atypical and idio-pathic parkinsonism[J].Neurosci Lett,2008,441(2):158-162.
[29]Horne BD,Muhlestein JB,Carlquist JF,et al.Statin therapy interacts with cytomegalovirus seropositivity and high Creactive protein in reducing mortality among patients with angiographically significant coronary disease[J].Circulation,2003,107(2):258-263.
[30]Ulrich L,Fata VL,Plutzky J,et al.Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors[J].Circulati on,1998,97(12):1129-1135.
[31]Wolozin B,Wang SW,Li NC,et al.Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease[J].BMC Med,2007,5:20.
[32]Wahner AD,Bronstein JM,Bordelon YM,et al.Statin use and the risk of Parkinson disease[J].Neurology,2008,70:1418-1422.
[33]Kumar A,Sharma N,Gupta A,et al.Neuroprotective potential of atorvastatin and simvastatin(HMG-CoA reductase inhibitors)against6-hydroxydopamine(6-OHDA)induced Parkinson-like symptoms[J].Brain Res,2012,1471:13-22.
[34]Bosco DA,Fowler DM,Zhang Q,et al.Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerateal pha-synuclein fibrilization[J].Nat Chem Biol,2006,2:249-253.